These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 11103798

  • 1. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
    Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D.
    Cancer Res; 2000 Nov 15; 60(22):6359-66. PubMed ID: 11103798
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
    Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB.
    Clin Cancer Res; 2000 Mar 15; 6(3):798-806. PubMed ID: 10741699
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
    Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D.
    Gene Ther; 2001 Feb 15; 8(4):308-15. PubMed ID: 11313805
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G.
    Cancer Res; 2002 Feb 01; 62(3):764-72. PubMed ID: 11830531
    [Abstract] [Full Text] [Related]

  • 7. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
    Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D.
    Gene Ther; 2001 May 01; 8(10):746-59. PubMed ID: 11420638
    [Abstract] [Full Text] [Related]

  • 8. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.
    Gene Ther; 2005 Sep 01; 12(17):1333-46. PubMed ID: 15920462
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
    Heise C, Lemmon M, Kirn D.
    Clin Cancer Res; 2000 Dec 01; 6(12):4908-14. PubMed ID: 11156251
    [Abstract] [Full Text] [Related]

  • 11. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
    Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng X.
    Ai Zheng; 2004 Dec 01; 23(12):1666-70. PubMed ID: 15601557
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
    Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K, Lu M, Aguilar-Cordova E, Kim JH.
    Cancer Res; 2002 Sep 01; 62(17):4968-76. PubMed ID: 12208748
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas.
    Shinoura N, Yoshida Y, Tsunoda R, Ohashi M, Zhang W, Asai A, Kirino T, Hamada H.
    Cancer Res; 1999 Jul 15; 59(14):3411-6. PubMed ID: 10416603
    [Abstract] [Full Text] [Related]

  • 15. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.
    Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH.
    Cancer Res; 2000 Mar 01; 60(5):1193-6. PubMed ID: 10728673
    [Abstract] [Full Text] [Related]

  • 16. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity.
    Milas M, Yu D, Lang A, Ge T, Feig B, El-Naggar AK, Pollock RE.
    Cancer Gene Ther; 2000 Mar 01; 7(3):422-9. PubMed ID: 10766348
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
    Zhang SW, Xiao SW, Liu CQ, Sun Y, Su X, Li DM, Xu G, Zhu GY, Xu B.
    Zhonghua Zhong Liu Za Zhi; 2005 Jul 01; 27(7):426-8. PubMed ID: 16188130
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
    Sirianni N, Ha PK, Oelke M, Califano J, Gooding W, Westra W, Whiteside TL, Koch WM, Schneck JP, DeLeo A, Ferris RL.
    Clin Cancer Res; 2004 Oct 15; 10(20):6929-37. PubMed ID: 15501971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.